AstraZeneca's Imfinzi Approved In EU For Muscle-Invasive Bladder Cancer
4/7 08:13
(RTTNews) - British drug major AstraZeneca Plc. (AZN.L, AZN) announced Friday that Imfinzi (durvalumab) has been approved in the European Union for the treatment of adult patients with resectable muscle-invasive bladder cancer (MIBC) in combination with gemcitabine and cisplatin...